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Abstract
Background: Early in the pandemic, we designed a SARS-CoV-2 peptide vaccine containing epitope regions
optimized for concurrent B cell, CD4+ T cell, and CD8+ T cell stimulation. The rationale for this design was to drive
both humoral and cellular immunity with high specificity while avoiding undesired effects such as antibody-
dependent enhancement (ADE).
Methods: We explored the set of computationally predicted SARS-CoV-2 HLA-I and HLA-II ligands, examining
protein source, concurrent human/murine coverage, and population coverage. Beyond MHC affinity, T cell vaccine
candidates were further refined by predicted immunogenicity, sequence conservation, source protein abundance,
and coverage of high frequency HLA alleles. B cell epitope regions were chosen from linear epitope mapping
studies of convalescent patient serum, followed by filtering for surface accessibility, sequence conservation, spatial
localization near functional domains of the spike glycoprotein, and avoidance of glycosylation sites.
Results: From 58 initial candidates, three B cell epitope regions were identified. From 3730 (MHC-I) and 5045 (MHC-
II) candidate ligands, 292 CD8+ and 284 CD4+ T cell epitopes were identified. By combining these B cell and T cell
analyses, as well as a manufacturability heuristic, we proposed a set of 22 SARS-CoV-2 vaccine peptides for use in
subsequent murine studies. We curated a dataset of ~ 1000 observed T cell epitopes from convalescent COVID-19
patients across eight studies, showing 8/15 recurrent epitope regions to overlap with at least one of our candidate
peptides. Of the 22 candidate vaccine peptides, 16 (n = 10 T cell epitope optimized; n = 6 B cell epitope optimized)
were manually selected to decrease their degree of sequence overlap and then synthesized. The immunogenicity
of the synthesized vaccine peptides was validated using ELISpot and ELISA following murine vaccination. Strong T
cell responses were observed in 7/10 T cell epitope optimized peptides following vaccination. Humoral responses
were deficient, likely due to the unrestricted conformational space inhabited by linear vaccine peptides.
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Conclusions: Overall, we find our selection process and vaccine formulation to be appropriate for identifying T cell
epitopes and eliciting T cell responses against those epitopes. Further studies are needed to optimize prediction
and induction of B cell responses, as well as study the protective capacity of predicted T and B cell epitopes.
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Background
SARS-CoV-2 vaccines have largely focused on generation
of B cell responses to trigger production of neutralizing
antibodies [1–3]. SARS-CoV-2 enters cells through inter-
action of the viral receptor binding domain (RBD) with
angiotensin-converting enzyme 2 (ACE2) receptors, found
on the surface of human nasopharyngeal, lung, and gut mu-
cosa [4]. Neutralizing antibodies targeting the RBD and
other functional domains of the SARS-CoV-2 spike protein
are a major route for achieving immunity and vaccine effi-
cacy [5–10]. When work on this study began in March
2020, little was known about the relative contribution of
different adaptive immune compartments to immunity
against SARS-CoV-2. Broadly, it was understood that CD4+
and CD8+ T cells have roles in the antiviral immune re-
sponse, including against SARS-CoV-1 [11–13]. Prior stud-
ies in SARS-CoV-1 have demonstrated T cell responses
against viral epitopes, with strong T cell responses corre-
lated with generation of higher neutralizing antibody titers
[13]. Unlike antibody epitopes, T cell epitopes need not be
limited to accessible regions of surface proteins. In SARS-
CoV-1, concurrent CD4+ and CD8+ activation and central
memory T cell generation were induced in exposed pa-
tients, with increased Th2 cytokine polarization observed in
patients with fatal disease [13]; conversely, Th1 response
has been associated with less severe disease in SARS-CoV-2
[14]. Additionally, Type 1 and Type 2 immunity are not
strictly synonymous with cell-mediated and humoral im-
munity, respectively, with Th1 polarization capable of indu-
cing moderate antibody production [15]. Because of these
considerations, most groups developing vaccines for SARS-
CoV-2 have focused on promoting Th1 response due to
safety concerns and demonstrated efficacy of Th1 response
[16]. To this end, we deduced that vaccines targeting
humoral (B cells) and cytotoxic arms (CD8+ T cells) with
concurrent helper signalling (CD4+ T cells), delivered with
adjuvants promoting Th1 polarization, may provide optimal
immunity against SARS-CoV-2.
In the intervening year, many vaccine strategies for
SARS-CoV-2 have demonstrated efficacy in clinical tri-
als, including mRNA encoding of the spike glycoprotein,
recombinant spike protein, adenovirus vector expressing
the surface glycoprotein, as well as delivery of whole
inactivated virus [2, 3, 17–25]. These strategies have
proven successful at eliciting neutralizing antibody re-
sponses against conformational epitopes [26] and offer
impressive protection from both infection and disease
[22, 23, 27, 28]. More recently, however, concern has
emerged regarding the rapid evolution [29, 30] of the
virus with concomitant decrease or loss of neutralization
from some novel variants [31–33]. Currently circulating
variants, however, do not appear to abrogate T cell re-
activity [34] and there is hope that vaccine induced T
cell responses provide a second line of defense against
viral infection [35, 36]. Whether future variants would
also be recognized by T cell evolutionary pressure to es-
cape T cell responses is unclear. Multi-epitope peptide
vaccination is an alternative approach which targets
smaller antigenic fragments of viral proteins. Peptide
vaccines have historically been most successful at elicit-
ing T cell responses [37–40] and, in certain pathogens,
they have also been able to elicit neutralizing antibodies
against linear epitopes [41–44]. Peptide vaccines may
have a complementary role relative to existing SARS-
CoV-2 vaccines due to their history of safe administra-
tion [45–48], rapid development [49, 50], and precise
selection of antigenic content. A peptide vaccine can
easily exclude polymorphic antigenic regions or be up-
dated to include antigenic fragments from newly emer-
ging variants.
We report here a design methodology for selecting
SARS-CoV-2 vaccine peptides which combines linear B
cell epitopes with both CD4+ and CD8+ T cell epitopes,
as well as an evaluation of our strategy based on a mur-
ine vaccination study and a comparison with a curated
dataset of published SARS-CoV-2 T cell epitopes (Fig. 1).
We start with a survey of the T and B cell epitope space
of SARS-CoV-2 (Fig. 2). Predicted T cell epitopes were
derived from in silico predictions filtered on binding af-
finity and immunogenicity models generated from epi-
topes deposited in the Immune Epitope Database (IEDB)
[51], population diversity, and source protein abundance
in order to select peptides that bind common HLA al-
leles and are likely to generate robust CD8+ and CD4+ T
cell activity. B cell epitope candidates were curated from
linear epitope mapping studies and further filtered by
accessibility, glycosylation, polymorphism, and adjacency
to functional domains to identify peptides most likely to
generate robust antibody responses. Given the utility of
murine-adapted SARS-CoV-2 models for evaluating vac-
cine candidates [7, 52–54], we also identified peptides
derived from viral proteins predicted to bind murine
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MHC coded for by H2-Db/d, H2-Kb/d, and H2-IAb/d hap-
lotypes. We then selected 22 longer sequence regions for
use as vaccine antigens. These vaccine peptides each
span multiple predicted CD4+/CD8+ T cell and linear B
cell epitopes, along with predicted murine MHC-I/II
ligands. We compared this vaccine peptide selection
process with a curated dataset of eight studies mapping
SARS-CoV-2 T cell epitopes from COVID-19 patients
and found that many of the recurrent epitope regions
were captured by our vaccine peptides. We also
Fig. 1 Visual summary of T and B cell epitope vaccine prediction and validation. (1) We explored the set of computationally predicted SARS-CoV-
2 HLA-I and HLA-II ligands, examining source protein abundance, sequence conservation, coverage of high frequency HLA alleles, and predicted
immunogenicity. (2) B cell epitope regions were chosen from linear epitope mapping studies of convalescent patient serum, followed by filtering
for sequence conservation, surface accessibility, spatial localization near functional domains of the spike glycoprotein, and avoidance of
glycosylation sites. (3) Vaccine selection of 27mers peptides was performed by optimizing population HLA coverage of T cell epitopes, evaluating
human/murine MHC ligand co-coverage, as well as examining peptides with optimal coverage of B cell, CD4+, and CD8+ epitopes. (4) Lastly,
validation was performed through comparison against a curated dataset of ~ 1000 observed T cell epitopes from convalescent COVID-19 patients
across eight studies, as well as murine ELISA/ELISpot studies using animals vaccinated with synthetic 27mer peptides with human/murine
epitope co-coverage
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evaluated 16 of the 22 vaccine peptides in a murine vac-
cination experiment and found that the same subset of
the peptides elicited T cell responses in combination
with two different adjuvants.
Methods
Antibody epitope curation
Linear B cell epitopes on the SARS-CoV-2 surface
glycoprotein were curated from five published studies
[55–59]. Four of these studies screened polyclonal sera
of convalescent COVID-19 patients using either peptide
arrays [55, 56, 59] or phage immunoprecipitation se-
quencing (PhIP-Seq) [57]. One study characterized the
epitopes of monoclonal neutralizing antibodies [59].
Results from Schwarz et al. included sera from six
SARS-CoV-2-naive patient sera and nine SARS-CoV-2-
infected patient sera using PEPperCHIP® SARS-CoV-2
Proteome Microarrays [59]. The peptides included in
these proteome-wide epitope mapping analyses were
limited to those which demonstrated either IgG or IgA
fluorescence intensity > 1000 U in at least two infected
patient samples and in none of the naive patient sam-
ples. In addition, two peptides were also included
(QGQTVTKKSAAEASK, QTVTKKSAAEASKKP) which
demonstrated IgG fluorescence intensity > 1000 U in
only one naive patient sample each, but in four and five
infected patient samples, respectively.
HLA ligand prediction
The SARS-CoV-2 protein sequence FASTA was re-
trieved from the NCBI reference database (https://www.
ncbi.nlm.nih.gov/nuccore/MT072688) [60]. Haplotypes
included in this analysis were derived from those with >
5% expression within the United States populations
based on the National Marrow Donor Program’s Haplo-
Stats tool [61]:
 HLA-A: A*11:01, A*02:01, A*01:01, A*03:01,
A*24:02
 HLA-B: B*44:03, B*07:02, B*08:01, B*44:02, B*44:03,
B*35:01
 HLA-C: C*03:04, C*04:01, C*05:01, C*06:02,C*07:01,
C*07:02
 HLA-DR: DRB1*01:01, DRB1*03:01, DRB1*04:01,
DRB1*07:01, DRB1*11:01, DRB1*13:01, DRB1*15:01
Additionally, HLA-DQ alpha/beta pairs were chosen
based on prevalence in previous studies [62]:






For HLA-I, 8-11mer epitopes were predicted using
netMHCpan 4.0 [63] and MHCflurry 1.6.0 [64]. For
HLA-II calling, 15mers were predicted using
NetMHCIIpan 3.2 [65] and NetMHCIIpan 4.0 [66].
For optimization of epitope predictions, individual
features from each HLA-I and HLA-II prediction
tool was compared against IEDB binding affinities
using Spearman correlation (Additional file 1: Fig.
S1). Cutpoints for the best performing HLA-I and
HLA-II feature were set using 90% specificity of pre-
dicting for peptides with < 500 nM binding affinity
Fig. 2 Summary of B cell and CD4+/CD8+ epitope prediction workflows. Pathways are colored by B cell (blue), human T cell (black), and murine T
cell (red) epitope prediction workflows. Color bars represent proportions of epitopes derived from internal proteins (ORF), nucleocapsid
phosphoprotein, and surface-exposed proteins (spike, membrane, envelope)
Smith et al. Genome Medicine          (2021) 13:101 Page 4 of 23
in the IEDB set, using predicted binding affinity
values from netMHCpan 4.0 (HLA-I) and netMH-
CIIpan 3.2 (HLA-II). The proportion of the total
U.S. population containing at least one haplotype
capable of binding each peptide was calculated as-




1− f ið Þ2
Immunogenicity modeling
IEDB HLA-I and HLA-II viral tetramer data were used
to generate a generalized linear model (GLM; family =
binary) with tetramer-positivity as a binary outcome
[51]. Independent variables for HLA-I included
NetMHCpan 4.0 binding affinity and elution score,
MHCflurry binding affinity, presentation score, process-
ing score, and percentage of aromatic (F, Y, W), acidic
(D, E), basic (K, R H), small (A, G, S, T, P), cyclic (P),
and thiol (C, M) amino acid residues. Independent vari-
ables for HLA-II included NetMHCIIpan 4.0 binding af-
finity and elution scores, and percentage of aromatic,
acidic, basic, small, cyclic, and thiol amino acid residues.
All independent variables were normalized to 0–1 to
keep coefficients comparable (binding affinities divided
by 50,000). GLM model performance was derived using
5-fold cross-validation, balancing for HLA alleles. The
final HLA-I and HLA-II models were generated using
each full IEDB set, then applied to SARS-CoV-2 pre-
dicted HLA ligands to derive a GLM score. For im-
munogenicity filtering, predicted epitopes above the
median GLM score were kept.
B cell epitope selection
Accessibility of contiguous regions of the spike protein
was approximated with the following heuristic: mean ac-
cessibility of 35%, minimum accessibility of 15%, requir-
ing at least one residue to have accessibility greater than
50%, and the ends of a region to have at least 25% acces-
sibility. Adjacency to a functional region was defined as
within 15aa of either side of FP, HR1, and HR2, and
within 50aa of the RBD. A broader window was used for
the receptor binding domain due to the known presence
of neutralizing antibody epitopes in S1 of SARS-CoV-1
outside of the RBD [67].
Published T cell epitope data curation
T cell epitopes from eight studies of immune responses
from convalescent COVID-19 patients [68–75] were
manually curated into a spreadsheet with 973 entries
(Table S9). Other studies were excluded which focused
on murine immune responses and/or immunity from
vaccination. To aggregate epitope regions of varying
granularities, the viral proteome was split into 40aa bins,
overlapping by 20aa. A bin was considered to contain an
epitope region if they overlapped by at least 8aa. Simi-
larly, each vaccine peptide counted as overlapping a bin
if their overlap was at least 8aa. Overlapping bins were
mutually exclusive, and only the bin with the highest
number responding patients was retained. Bin boundar-
ies were then clipped to the minimum and maximum
boundaries of any epitope region contained within it.
Vaccine peptide manufacturability
Based on previous experiences with peptide synthesis
failures and consultation with the UNC High-
Throughput Peptide Synthesis and Array Facility, we de-
vised a scoring rubric for solid-phase peptide synthesis
difficulty (Additional file 1: Fig. S8A). This rubric in-
cludes features related to the stability of the synthesized
peptide product as well as sequence features which in-
crease the difficulty of peptide elongation and/or purifi-
cation. For example, hydrophobic peptides are
challenging to solubilize, whereas hydrophobic regions
within peptides are challenging to elongate during syn-
thesis due to strong conformational properties. In our
scoring rubric, hydrophobicity of peptide sequences is
calculated using the mean GRAVY score [76], which is
computed both for the entire peptide as well as the max
for all local windows of lengths between 5mer and 8mer.
Local hydrophobicity scores are penalized proportional
to how much they exceed 2.5 whereas whole peptide
hydrophobicity is penalized to the degree that it exceeds
2. These values were determined based on unpublished
data relating to which peptides had failed for reasons re-
lated to hydrophobicity during the PGV001 neoantigen
vaccine trial [77]. Another category of difficulties relates
to the instability of certain pairs of adjacent amino acids.
The extremely unstable dipeptides are DG and NG,
whereas the less penalized but still problematic dipep-
tides are DS, DN, DD, NN, ND, NS, and NP. Further-
more, certain terminal residues inhibit the initiation of
synthesis or formation of undesired residues such as pyr-
oglutamate. Difficult N terminal residues are Q, E, C,
and N, whereas difficult C terminal residues are P, C,
and H. Lastly, the inclusion of multiple thiol residues
can be challenging due to formation of long-range disul-
fide bonds. Our heuristic penalizes both the total num-
ber of thiols (C and M residues), as well as a penalty for
excessive cysteines which is only applied when the num-
ber of C residues exceeds 1. Many of similar features are
enumerated in commercial peptide design guides, such
as ones published by Biomatik [78] and SB peptide [79]
or in standard texts on solid-phase synthesis [80]. The
particular weights given to different peptide features are
determined purely from experience and intuition and
are presented without claims of accuracy or optimality.
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SARS-CoV-2 entropy calculations
In total, 7881 SARS-CoV-2 genome sequences were
downloaded from GISAID (https://www.gisaid.org/) [81].
A preprocessing step removed 127 sequences that were
shorter than 25,000 bases. The sequences were split into
79 smaller files and aligned using Augur [82] (which re-
lies on the MAFFT [83] aligner) with NCBI entry
MT072688.1 [84] as the reference genome. The refer-
ence genome was downloaded from NCBI GenBank
[85]. The 79 resulting alignment files were concatenated
into a single alignment file with the duplicate reference
genome alignments removed. The multiple sequence
alignment was translated to protein space using the R
packages seqinr [86] and msa [87]. Entropy for each pos-
ition was calculated using the following formula, where
n is the number of possible outcomes (i.e., total unique
identifiable amino acid residues at each location) and pi
is the probability of each outcome (i.e., probability of




pi  log pið Þ
Mouse vaccination
All mouse work was performed according to IACUC
guidelines under UNC IACUC protocol ID 20-121.0.
Vaccine studies were performed using BALB/c mice with
free access to food and water. Mice were ordered from
Jackson Laboratories and vaccinated at 8 weeks of age.
Equal numbers of male and female mice were used per
group, vaccinated with poly(I:C) (Sigma-Aldrich cat.
#P1530) either alone or in combination with 16 synthe-
sized vaccine peptides. In total, 26 μg total peptide was
utilized per vaccination (divided equimass per peptide).
Then, 75 μg of polyI:C was utilized per vaccination, with
n = 6 mice per experimental group and n = 3 mice per
polyI:C-only control group. Mice were vaccinated on
days 1 and 7, cheek bleeds obtained on days 7 and 14,
and sacrificed with cardiac bleeds performed on day 21.
S Protein ELISA
Serum obtained from cardiac bleeds on day 21 was uti-
lized for ELISA testing for antibody response to SARS-
CoV-2 spike (S) protein. Nunc Maxisorp plates (Thermo
Fisher Scientific) were coated with S protein (generously
provided by Ting Lab at UNC), or BSA as a negative
control and incubated overnight. Plates were blocked
with 10% FBS in PBS, washed, and serum plated in du-
plicate wells with serial dilutions. 6x His Tagged mono-
clonal antibody (Thermo Fisher Scientific) was also
plated as an experimental control. Goat anti-mouse IgG
HRP (Thermo Fisher Scientific) was added to washed
plates as a secondary antibody. TMB substrate (Thermo
Fisher Scientific) was added, development was stopped
with TMB Stop solution (BioLegend), and plates were
read at 450 nm.
Peptide ELISA
Serum obtained from cardiac bleeds on day 21 and
cheek bleeds on experimental days 7 and 14 were tested
for antibody response to the predicted B cell peptide epi-
topes used for vaccinations via peptide ELISAs. Plates
were coated with 5μg/mL of target peptide using coating
reagent from the Takara Peptide Coating Kit (Takara
cat. #MK100). Measles peptide was utilized as a negative
control, and Flag peptide was also plated as an experi-
mental control. Plates were blocked with a blocking buf-
fer according to the manufacturer’s protocol. Serum was
plated in duplicate wells with serial dilutions, and anti-
FLAG antibody was plated in the experimental control
wells. Rabbit anti-mouse IgG HRP (Abcam ab97046)
was utilized as a secondary antibody. TMB substrate
(Thermo Fisher Scientific cat. #34028) was added, devel-
opment was stopped with TMB Stop solution (BioLe-
gend cat. #423001), and plates were read at 450 nm.
ELISpot
After the sacrifice of mice on experimental day 21,
spleens were dissected out for ELISpot assessment of T
cell activation in response to peptide and adjuvant vac-
cination. Spleens were mechanically dissociated using a
GentleMACS Octo Dissociator (Miltenyi Biotec) and
passed through a 70-μm filter. RBC lysis buffer (Gibco
cat. #A1049201) was used to remove red blood cells, and
cells were washed then passed through 40-μm filters.
Splenocytes were counted and 250,000 splenocytes were
plated per well into plates (BD Biosciences; cat.
#551083) that had been coated with each of the individ-
ual 16 predicted target peptides, or PBS as negative
control or PHA as experimental control. Plates were in-
cubated for 72 h. Anti-interferon gamma detection anti-
body was added according to the manufacturer’s
protocol, followed by enzyme conjugate Streptavidin-
HRP and final substrate solution (BD Biosciences; cat.
#557630). Plates were allowed to develop, washed to
stop development, and allowed to dry before reading on
ELISpot reader (AID Classic ERL07).
Graphical and statistical analysis
Plots and analyses were generated using the following R
packages: caret 6.0-84 [88], cowplot 0.9.4 [89], data.table
1.12.8 [90], DESeq2 1.22.2 [91], doMC 1.3.6 [92], dplyr
0.8.4 [93], forcats 0.4.0 [94], GenomicRanges 1.34.0 [95],
ggallin 0.1.1 [96], ggbeeswarm 0.6.0 [97], ggnewscale
0.4.1 [98], ggplot2 3.3.0 [89], ggpubr 0.2 [99], ggrepel
0.8.1 [100], gplots 3.0.3 [101], gridExtra 2.3 [102], huxta-
ble 4.7.1 [103], magrittr 1.5 [104], officer 0.3.10 [105],
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pROC 1.16.2 [106], RColorBrewer 1.1-2 [107], readxl
1.3.1 [108], scales 1.1.0 [109], seqinr 3.6-1 [86], stringr
1.4.0 [110], venneuler 1.1-0 [111], viridis 0.5.1 [112]. Fig-
ures 4C, D and 5 were generated using the following Py-
thon packages: NumPy [113], pandas [114], Matplotlib
[115], and Jupyter [116].
Results
Landscape of MHC ligands in SARS-CoV-2
To determine the landscape of potential HLA ligands in
SARS-CoV-2 (Fig. 2, black), we first identified candidate
MHC ligands by performing HLA-I binding prediction
using NetMHCpan 4.0 (both EL (elution ligand) and BA
(binding affinity) mode) [63] and MHCflurry [64] (8–
11mers), and HLA-II binding prediction using NetMH-
CIIpan 3.2 [65] and 4.0 [66] (15mers), using alleles with
> 5% genetic frequency in the USA [61, 62] and world-
wide populations [117] (full predicted sets for U.S.
alleles: Table S1, S2; worldwide alleles: Table S3, S4). To
assess the accuracy of these peptide/MHC binding pre-
diction tools on viral peptides, we tested their perform-
ance on IEDB MHC affinity assay data values for viral
peptides. Of the predictive models evaluated, NetMHC-
pan 4.0 (BA) and NetMHCIIpan 3.2 demonstrated the
highest correlation of binding affinity predictions for
Class I and Class II MHC, respectively (Additional file 1:
Fig. S1A-B). Therefore, these two predictors were used
for predicting MHC ligands. A measured peptide/MHC
binding affinity of 500 nM or less is commonly used to
identify MHC-binding peptides which are more likely to
be T cell epitopes [118, 119]. To account for the inaccur-
acy inherent to prediction (as opposed to measurement)
of peptide-MHC affinity, we derived slightly stricter cut-
offs. In order to achieve 90% specificity in IEDB binding
affinity data (validated ligand set), we use predicted bind-
ing affinity thresholds of 393.4 nM and 220.0 nM for Class
I and Class II MHC, respectively (Additional file 1:
Fig. 1C-D). This filter was applied to NetMHCpan 4.0 and
NetMHCIIpan 3.2 SARS-CoV-2 MHC binding predic-
tions, which removed the majority of viral protein sub-
sequences (Additional file 1: Fig. 2A-B).
After filtering by binding affinity, we observed a total
of 2486 unique HLA-I ligands and 3138 unique HLA-II
ligands (Fig. 3C). Predicted MHC ligands were not
evenly distributed across the proteome, with local peaks
and troughs observed that correlated between HLA-I
and HLA-II ligands (Fig. 3C, bottom; Pearson correl-
ation of HLA-I/II LOESS, r = 0.703, p < 0.001). Notably,
while SARS-CoV-1 T cell epitopes previously described
in the literature were primarily located in the surface
glycoprotein (S) and nucleocapsid protein (N) (Table S5)
[13, 120–145], we observed a paucity of predicted MHC
ligands in the N protein. As murine models for SARS-
CoV-2 would be a powerful tool in understanding viral
immunobiology, we determined which predicted HLA li-
gands were also predicted to bind murine MHC alleles
of the H2b and H2d haplotypes. NetMHCpan and
NetMHCIIpan were run using the SARS-CoV-2 prote-
ome against the H2b and H2d haplotypes, filtering by
MHC-I ligands in the top 2nd percentile (n = 3053) and
MHC-II ligands in the top 10th percentile (n = 1648).
From this set, we observed an overlap of 887 peptides in
MHC-I and 1571 peptides in MHC-II between murine
and human sets (Fig. 3D). For the nested HLA ligand
set, we observed 825 and 848 overlapping murine MHC-
I and MHC-II ligands, respectively, with 846 HLA li-
gands containing both murine MHC-I and MHC-II
coverage. The majority of HLA ligand sequences were
predicted to bind to fewer than 50% of the U.S. popula-
tion, particularly for HLA-I ligands (Fig. 3E). In accord-
ance with higher population coverage distribution in
HLA-II, predicted HLA-II ligands also demonstrated
more binding alleles on average (mean alleles per pep-
tide: HLA-I = 1.35, HLA-II = 2.80). Among the most
common alleles were HLA-A*02:01 (n = 784), HLA-
A*11:01 (n = 643), and HLA-A*03:01 (n = 383) for pre-
dicted HLA-I binding peptides and HLA-DRB1*01:01 (n
= 5401), HLA-DRB1*07:01 (n = 3225), and HLA-
DRB1*13:01 (n = 3022) for predicted HLA-II binding
peptides.
CD8+ and CD4+ T cell epitope prediction
Peptide/MHC binding is necessary but not sufficient for
peptide epitopes to elicit T cell responses. We sought to
identify a set of epitopes that would serve as good tar-
gets for a SARS-CoV-2 T cell vaccine. From the total
pool of HLA-I, HLA-II, and nested MHC ligands, we
sought to prioritize sequences which are predicted to be
immunogenic from highly conserved regions of abun-
dant viral proteins (Fig. 4, middle).
To predict the immunogenicity of MHC ligands, we fit
a forward stepwise multivariable logistic regression
model using peptide/HLA tetramer flow cytometry data
curated from viral entries of the IEDB [51]. Tetramer
data was selected for the response variable because it
provides unambiguous association between a peptide
and its bound MHC, and additionally tests which
specific peptide/MHC is capable of eliciting a T cell re-
sponse. Each unique peptide-MHC was encoded with
features derived from epitope prediction tools as well as
features relating to amino acid content (see “Immuno-
genicity modeling”). Epitope prediction tool features
were selected to allow for consideration of predicted
binding affinity alongside other tangential features such
as MHC ligand elution (NetMHCpan 4.0, NetMHCIIpan
4.0) and antigen processing (MHCflurry), while amino
acid content was considered due to prior studies demon-
strating capacity of these features to predict for epitope
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immunogenicity [146, 147]. Model performance in 5-
fold cross-validation demonstrated AUC values of
approximately 0.7 and 0.9 for HLA-I and HLA-II, re-
spectively, in both training and test sets Additional file 1:
Fig. S2A-B). Models demonstrated cleaner separation of
tetramer positive and negative groups for CD4+ epitopes
compared to CD8+ (Additional file 1: Fig. S2C-D). To
determine a cause for this difference in model perform-
ance, we examined predicted binding affinity scores
between tetramer positive and negative epitopes, which
demonstrated significantly better separation for CD4+
epitopes than CD8+ epitopes (Additional file 1: Fig. S2E-
F). In accordance with this difference in binding affinity
distribution, the HLA-II model showed strong associ-
ation between lower binding affinity and lower predicted
tetramer positivity, while the HLA-I model showed a
weaker inverse association (Additional file 1: Fig. S3).


















Fig. 3 Landscape of SARS-CoV-2 MHC ligands. A,B Selection criteria for A HLA-I and B HLA-II SARS-CoV-2 HLA ligand candidates. Scatterplot
(bottom) shows predicted (x-axis) versus IEDB (y-axis) binding affinity, with horizontal line representing 500 nM IEDB binding affinity and vertical
line representing corresponding predicted binding affinity for 90% specificity in binding prediction. Histogram (top) shows all predicted SARS-
CoV-2 HLA ligand candidates. Scatterplot in B shows subsampled points from HLA-DRB1 alleles (< 50 points per allele) to allow for increased
visibility of points. C Landscape of predicted HLA ligands, showing HLA-I (red) and HLA-II (blue) ligands with U.S. population coverage > 50%
(top), and LOESS fitted curve (span = 0.1) for HLA-I/II ligands by location along the SARS-CoV2 proteome (color tracks). The predicted binding
affinity of HLA ligand peptides to murine H2-b/d alleles is represented with point shading. D Summary of murine/human MHC ligand overlap.
E Distribution of population frequencies among predicted HLA-I and HLA-II ligands
Smith et al. Genome Medicine          (2021) 13:101 Page 8 of 23
between IEDB HLA-I and HLA-II tetramer sets, a
performance-based cutoff did not allow for equal filter-
ing of CD4+ and CD8+ epitopes. Therefore, we filtered
by generalized linear model (GLM) predicted immuno-
genicity scores above the median in each HLA-I/II
SARS-CoV-2 epitope group, which provided balanced
selection while removing predicted low-immunogenicity
epitopes (Additional file 1: Fig. S4).
Next, we sought to prioritize epitopes derived from re-
gions of low sequence variation across viral strains. A
position-based entropy filter was applied to all epitopes
(Additional file 1: Fig. S5), keeping those with an entropy
score ≤ 0.1 (~ 98% sequence identity, n = 7881) in all
amino acid positions across MSA-aligned SARS-CoV-2
genomes downloaded from the GISAID database [81,
82]. High entropy was observed in the well-described
spike protein D614G polymorphic site (Additional file 1:
Fig. S5A, red dot). Other areas of high entropy included
positions 3606, 4715, 5828, and 5865 of ORF1ab, and








Fig. 4 Prediction of SARS-CoV-2 T cell epitopes. (Top) Summary of predicted and IEDB-defined HLA-I (left) and HLA-II (right) SARS-CoV-2 HLA
ligands, showing proportions of each derivative protein. (Middle) Funnel plot representing counts of HLA-I (left) and HLA-II (right) ligands along
with proportions of HLA-I (top bar) and HLA-II (bottom bar) alleles at each filtering step. (Bottom) Summary of CD8+ (red, top), CD4+ (blue,
bottom), and nested T cell epitopes (middle) after filtering criteria in S, M, and N proteins. Y-axis and size represent the U.S. population frequency
of each CD8+ and CD4+ epitopes by circles. Middle track of diamonds represents overlaps between CD8+ and CD4+ epitopes, showing the
overlap with greatest population frequency (size) for each region of overlap. Color of diamonds represents the proportion of overlap between
CD4+ and CD8+ epitope sequences
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majority of positions demonstrated > 95% sequence
identity, suggesting high homology between different
SARS-CoV-2 viral genomes (Additional file 1: Fig. S5B).
Lastly, as the likelihood of MHC presentation is corre-
lated with protein expression [148], we filtered epitopes
to those derived from the S, M, and N proteins. These
were the three highest expressed proteins based on a
semi-quantitative mass spectrometry analysis of SARS-
CoV-2 protein expression (PSM count/protein length;
Additional file 1: Fig. S6A) [149]. This protein abun-
dance estimation closely matched expression levels de-
rived from SARS-CoV-2 RNA-seq data (Additional
file 1: Fig. S6B) [150]. After all these filtering steps, 292
CD8+, 616 CD4+, and 423 nested T cell epitopes were
predicted. We cross-filtered these epitopes against a ref-
erence peptidome of 8-11mer and 15mer peptides de-
rived from the GRCh38 reference proteome [151] and
observed no overlap. Relative proportions of HLA alleles
were conserved throughout filtering (Fig. 4, middle). Full
peptide sets with all filtering criteria are listed in Tables
S1 (HLA-I) and S2 (HLA-II).
B cell epitope prediction
In addition to identifying SARS-CoV-2 T cell epitopes,
we sought to identify a set of linear B cell epitopes on
the spike protein which would serve as good targets for
stimulating neutralizing antibody responses (Fig. 2). Epi-
tope candidates were derived from four published pre-
print mapping/array studies [55, 56, 58, 59] including a
PEPperCHIP® peptide array study [59] (for study details
see “Antibody epitope curation”). Starting with an initial
candidate pool of 58 linear epitopes with data to support
in vivo generation in humans (Fig. 5A, Table S6), we ap-
plied a set of filtering criteria to narrow our target space
(Fig. 5B):
1. Contiguous sub-sequences of the spike protein with
high accessibility
2. Exclude glycosylation sites
3. Exclude regions with significant polymorphism
between SARS-CoV-2 strains
4. Keep candidate epitopes within or adjacent to
functional domains with evidence of antibody-
mediated viral neutralization in SARS-CoV-1 (re-
ceptor binding domain, fusion peptide, heptad re-
peat regions)
5. Exclude any candidates shorter than four amino
acids
We used SARS-CoV-2 S protein accessibility data
from Grant et. al. [152], which calculates accessibility
from molecular dynamics simulations of a spike protein
structure with several different glycosylation patterns.
Unfortunately, this accessibility data lacks HR2, causing
that domain to be left out from subsequent analyses.
After filtering for contiguously accessible regions, there
were 19 remaining under consideration. Since many epi-
topes occur in multiple sources, we combined overlap-
ping epitope candidates into 14 unique sequences. After
filtering out epitopes containing glycosites, which may
alter antibody binding characteristics [153, 154], 11 non-
glycosylated regions remained. Two additional regions
were removed because they contained polymorphic sites,
defined by mutation frequency > 0.1% from GISAID
SARS-CoV-2 viral sequences. Of the remaining 9 re-
gions, only 4 were close to functional domains which in
the closely related virus SARS-CoV-1 have evidence of
antibody-mediated viral neutralization: the RBD, fusion
protein (FP), and heptad repeats [155–160]. This filter-
ing resulted in four remaining regions, of which our final
criteria removed one which had length less than four
residues (Fig. 5B). This filtering criteria precluded the
vast majority of total spike protein regions (Fig. 5C),
with three predicted antibody binding regions (residue
lengths 18, 4, and 4) remaining (Fig. 5D). All three epi-
tope candidate regions were present on solvent-exposed
surfaces of the S protein trimer 3D structure (Fig. 5E). It
is worth noting that the largest region, residues 456-473
within the receptor binding motif (RBM) loop, is only
accessible when the RBD is in the “open” conformation.
Selection of human and murine SARS-CoV-2 vaccine
peptides
With the above filters applied to predicted T and B cell
epitope candidates, we derived a minimal collection of
long vaccine peptides for all combinations of the follow-
ing immunological criteria: CD4+ responses, CD8+ re-
sponses, coverage of predicted B cell epitopes, along
with optional inclusion of predicted murine MHC li-
gands. A 27mer sequence for each vaccine peptide was
selected to maximize U.S. population coverage of T cell
epitopes within a peptide set, with or without additional
coverage for murine H2b, H2d, or both haplotypes
(Fig. 6A-B; Additional file 1: Fig. S7). If population
coverage was identical for multiple candidates, peptides
were also optimized based on a manufacturability diffi-
culty scoring system (Additional file 1: Fig. S8). The pep-
tide sequence length was inspired by previous work in
cancer neoantigen vaccination [161–163] which has
demonstrated strong CD8+ and CD4+ responses using
27mer peptides. Optimizing for CD4+ epitope popula-
tion coverage demonstrated 88.5% population frequency
encompassed by three 27mer peptides (Fig. 6B: 1, 9, and
15), while CD8+ epitope optimization provided 95.8%
population frequency coverage by three 27mer peptides
(Fig. 6B: 1, 4, and 14). CD4+/CD8+ co-optimization pro-
vided the best overall population coverage at 81.6%
population frequency with four 27mer peptides (Fig. 6B:






Fig. 5 Selection of SARS-CoV-2 B cell epitope regions. A SARS-CoV-2 linear B cell epitopes curated from epitope mapping studies. X-axis represents
amino acid position along the SARS-CoV-2 spike protein, with labeled start sites. B Schematic for filtering criteria of B cell epitope candidates. C Amino
acid sequence of spike protein domains considered for B cell epitope selection, with overlay of selection features prior to filtering. Polymorphic
residues are red, glycosites are blue, accessible regions highlighted in yellow. The receptor binding domain (RBD), fusion peptide (FP), and HR1 regions
are outlined. HR2 excluded for lack of accessibility data. D Spike protein functional regions (RBD, FP, HR1) amino acid sequences, with residues colored
by how many times they occur in identified epitopes. Selected accessible sub-sequences of known antibody epitopes highlighted in purple outline.
E S protein trimer crystal structure with glycosylation, with final linear epitope regions highlighted by color
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1, 6, 9, 13). While B cell epitope optimization provided
CD8+ coverage above 85%, CD4+ coverage was only
52.8%, suggesting the design of a combination B cell/
CD4+ T cell vaccine requires use of non-spatially over-
lapping sequences. Overall, selection of peptides which
also provided both H2b and H2d epitope coverage did
not greatly impact population coverage, suggesting these
murine-encompassing sets may allow for vaccine studies
in animal models whilst preserving human relevance.
Across the different selection criteria for minimal vac-
cine peptide sets, there was significant redundancy. Col-
lapsing the set of vaccine peptides by unique sequences
results in a final set of 22 27mer vaccine peptides
(Fig. 6B). In addition to 27mer peptides, all individual T/
B cell epitopes (S, M, and N: Table S7; all proteins:
Table S8) as well as 15mer (Additional file 1: Fig. 9) and
Fig. 6 T cell and B cell vaccine candidates. A 27mer vaccine peptide sets selecting for best CD4+, CD8+, CD4+/CD8+, and B cell epitopes with
HLA-I, HLA-II, and total U.S. population coverage. B Unified list of all selected 27mer vaccine peptides. Vaccine peptides containing predicted
ligands for murine MHC alleles (H2-b and H2-d haplotypes) are indicated in their respective columns
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21mer (Additional file 1: Fig. S10) optimized peptide sets
are also available.
Validation of T cell predictions by comparison with
recurrent published T cell epitopes from COVID-19
patients
To determine how our predictions of CD8+ and CD4+ T
cell epitopes relate to actual SARS-CoV-2 T cell epitopes,
we curated a dataset of published T cell epitope mapping
studies (Table S9) and compared recurrent epitope re-
gions with vaccine peptides. We focused on human stud-
ies of infection induced immunity, excluding murine and
vaccine studies, as well as excluding studies which only
performed TCR sequencing. We were able to curate eight
diverse studies [68–74, 164] whose study characteristics
are summarized in Fig. 7A. The T cell response assays in-
cluded ELISpot, MHC multimers, MIRA [165], AIM
[166], and T-Scan [167]. It is important to note that not
all studies examined responses to the same proteins or
even the same peptides within a protein. Some studies
conducted exhaustive unbiased tiling over the viral prote-
ome [68, 72, 74, 164], while others used computational
predictions of MHC affinity to select small sets of peptides
[68–71, 73]. Of these studies, only those which used mul-
timeric MHC assays were able to unambiguously identify
biological HLA restriction and the exact peptide determi-
nants of a T cell response, whereas others used predicted
or statistical assignments, sometimes within large peptide
windows. To overcome the heterogeneity of this dataset,
we binned the viral proteome into regions of 40 amino
acids into which each study could contribute one or more
identified epitope regions. A small number of recurrent
epitope regions contained responses from three or more
studies (Fig. 7B). Inspection of these recurrent regions
broadly confirms the choice of S and N as particularly im-
munogenic proteins, likely due to their abundance, as well
as one recurrent epitope region in the M protein. We also
see strong recurrent responses to two regions of ORF3a,
as well as three regions within non-structural proteins
contained within ORF1ab (nsp3, nsp12, nsp13), which
were not selected for consideration in our study. The
identified recurrent epitope regions were strongly
enriched for overlap with vaccine peptides selected in this
study. In fact, 8/15 recurrent epitope regions in the S, M,
and N proteins (and 8/20 total recurrent epitope regions)
significantly overlapped at least one vaccine peptide. This
degree of concordance gives us confidence that our com-
putational selection process for T cell epitopes is at least
to some degree predictive of biological SARS-CoV-2 T cell
epitopes following infection.
Murine validation of T and B cell epitope immunogenicity
We sought to experimentally evaluate our minimum set
of predicted T and B cell epitope candidates. We
manually selected 16 of the 22 vaccine peptides for syn-
thesis, keeping at most 2 peptides per overlapping region
with a preference for those with predicted H2d MHC li-
gands. We then vaccinated BALB/c mice with the 16
synthesized vaccine peptides and evaluated immune acti-
vation from humoral and T cell perspectives. Mice were
vaccinated on experimental day 1, given booster vaccin-
ation on day 7, and sacrificed on day 21. We performed
IFN-y ELISpot in order to assess T cell activation by cul-
turing splenocytes from vaccinated animals alongside
each of the peptides within the vaccine pool. We ob-
served a statistically significant increase in IFN-y release
in response to seven out of ten of our predicted T cell
epitopes in mice vaccinated with peptides plus poly(I:C)
versus poly(I:C) alone (Fig. 8A). We did not observe a
statistically significant response against any of our six
predicted B cell epitopes in our peptide vaccination
group versus adjuvant alone. For evaluation of antibody
responses, peptide (Fig. 8B) and S protein (Fig. 8C)
ELISA from the day 21 sera of the above mice failed to
show signal above adjuvant alone in all groups.
Discussion
We report here a survey of the SARS-CoV-2 epitope
landscape along with a strategy for prioritizing both T
cell and B cell epitopes for vaccine development. Major
vaccine efforts targeting coronaviruses have focused pri-
marily on generation of neutralizing antibody responses
[168–176]. CD4+ T cells provide help to B cells to sup-
port class switching, maturation, and antibody produc-
tion. Additionally, they promote CD8+ T cell activation,
maturation, and effector function. We therefore searched
for vaccine peptide sequences which include both B cell
epitopes and MHC ligands predicted to drive CD4+ and
CD8+ T cell responses at high population frequencies
within the U.S. based on data available in the first few
months of the pandemic. Our current efforts are focused
on testing the immunogenicity of these peptides in mur-
ine models, comparing those which contain overlapping
and non-overlapping T and B cell epitopes. Results from
such preclinical testing will inform an envisioned phase I
clinical trial using a condensed peptide set targeting B
cell epitopes with known viral neutralization plus opti-
mal T cell epitopes.
Prior work has surveyed the epitope space of SARS-
CoV-2 using analysis of sequence homology with SARS-
CoV-1 epitopes, prediction of linear B cell epitopes, and
prediction of T cell epitopes using IEDB tools. Grifoni
et al. reported predicted T and B cell epitopes based on
cross-referencing of known SARS epitopes with se-
quence homology to SARS-CoV-2 against SARS-CoV-2-
specific parallel computational prediction [177]. This
study did not consider epitope mapping of SARS-CoV-2
convalescent antibody repertoires, which may be
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important to achieve high specificity of B cell epitope
predictions. Our prediction of T cell epitopes is concep-
tually similar to their computational process, but our
study does not focus on conserved epitopes relative to
SARS-CoV-1. Instead, we attempt to filter CD4+, CD8+,
and B cell epitopes by additional considerations of vac-
cination suitability (e.g., polymorphism, accessibility) and
go beyond epitope selection to vaccine peptides integrat-
ing different categories of epitopes. Ahmed et al. re-
ported a set of predicted T and B cell SARS-CoV-2
Fig. 7 Evaluation of vaccine peptides based on published T cell responses in COVID-19 patients. A Overview of studies included in the T cell
validation dataset. B All regions (up to 40aa) of the SARS-CoV-2 proteome for which at least three of the eight studies observed either a CD4+ or
CD8+ T cell response. Fraction of circle fill corresponds to the largest fraction of patients with responses to any epitope in the region for a
particular study. Percentage column corresponds to percent of patients with positive response to an epitope in the region as a fraction of
patients evaluated. Overlapping vaccine peptides from this study are noted in the right-most column
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epitopes with associated assay confirmation within the
NIAID ViPR database. However, these predicted epi-
topes were largely limited to those with sequence hom-
ology between SARS-CoV-1 and SARS-CoV-2, given the
paucity of available SARS-CoV-2 assay data in the spring
of 2020. Several studies identified linear B cell epitopes
on the SARS-CoV-2 surface glycoprotein from sera of
viral exposed patients using peptide arrays [55, 56, 58] as
well as phage immunoprecipitation sequencing (PhIP-
Seq) [57]. These studies are an important source of in-
formation, but it has also been shown that antibodies
which recognize peptides often cross-react primarily
with proteins only in denatured conformations [178–
180]. There is a risk that identified linear epitopes would
not be able to promote viral neutralization in vivo due
to a lack of surface exposure. Our work adds to this im-
portant emerging field by analyzing the SARS-CoV-2
HLA ligand landscape through binding affinity filters de-
rived from validated IEDB HLA ligands, as well as deriv-
ing T and B cell vaccine candidates through rational
filtering criteria grounded in SARS-CoV-2 biology, in-
cluding predicted immunogenicity, epitope location, gly-
cosylation sites, and polymorphic sites. Additionally,
inclusion of corresponding murine epitopes allows for
future studies to be performed in animal models of
SARS-CoV-2. We expect the application of these filters
will improve specificity of antiviral response.
Other computational methods for prediction of SARS-
CoV-2 epitopes have been described [181–183] in a con-
tinuously growing body of literature. Many of these
studies consider population-specific MHC allele fre-
quencies and attempt to derive an optimal epitope set
that allows for broad population coverage. Liu et al.
[182] adds to this by further considering allelic linkage
Fig. 8 Experimental assessment of T and B cell epitope immunogenicity. A Mice were vaccinated with sixteen predicted T cell and B cell
epitopes, designated as “peptides,” in combination with poly(I:C), or with poly(I:C) alone. T cell activity in response to vaccination was measured
via IFN-y ELISpot with splenocytes isolated from mice at experimental day 21, plated with individual peptides. Activity was calculated by ELISpot
plate reader. Peptide designations indicate protein, start, and end as shown in Fig. 6B. B Antibody response against predicted B cell peptide
epitopes was measured via peptide ELISA. Wells were coated with pairs of predicted B cell peptides. C Antibody response against S protein was
assessed via whole protein ELISA. Response to bovine serum albumin (BSA) was measured as negative control. For all subfigures, asterisks indicate
statistically significant p value (< 0.05) from Mann-Whitney U tests of poly(I:C) + peptide groups compared to poly(I:C) alone
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disequilibrium. Omnibus analysis of peptide-MHC bind-
ing from previously described tools was used to identify
their peptide set comprising 19 each of MHC-I and
MHC-II ligands. This method differs from our strategy
in two ways: only considering peptide-MHC binding
prediction rather than filtering for putative T cell epi-
topes, and deriving a set of 38 total minimal MHC-I and
MHC-II ligands rather than identifying longer regions in
the SARS-CoV-2 proteome that encompass regions with
population-optimized T cell epitopes. While our capacity
to predict peptide-MHC binding is reasonably accurate
for MHC-I and variably accurate for MHC-II, our cap-
acity to predict immunogenicity of any given minimal
epitope remains limited. As such, we believe vaccinating
with a longer (27mer) sequence containing multiple pre-
dicted minimal epitopes allows for a degree of purpose-
ful imprecision, allowing for the optimal MHC-I and
MHC-II sequences to be processed and presented
in vivo. Compared to Poran et al. [181], which used a
mass spectrometry-derived HLA presentation predictor,
this peptide set is filtered through tetramer derived im-
munogenicity prediction—a more direct metric for epi-
tope efficacy. Yarmarkovich et al. [183] addresses
concerns for peptide immunogenicity versus auto-
immunity by comparing predicted epitopes against a ref-
erence human peptidome.
While this study also filters for peptide overlap with
self-epitopes, our immunogenicity prediction algorithm
primarily considers peptide sequence features inspired
by Calis et al. [146], predicted MHC scores, as well as
the MHCflurry 2.0 [184] peptide processing score for
CD8+ T cell epitopes, which are then used to fit a model
against a validated viral tetramer dataset curated from
IEDB [185]. Additionally, B cell epitopes were derived
from in silico methods in Yarmarkovich et al., while this
study used in vitro epitope mapping studies as the basis
for our B cell epitope candidate set. Lastly, Gao et al.
[186] approach the problem of SARS-CoV-2 epitope
prediction by directly evaluating a candidate peptide’s
sequence similarity to both the human proteome and
the set of pathogenic epitopes in IEDB; based on the
methodology, Luksza et al. [187] used for cancer neoan-
tigen prediction. This approach is intrinsically limited by
a hypothetical sequence homology between T cell epi-
topes in SARS-CoV-2 and previously identified patho-
genic epitopes. On the other hand, we use a diverse set
of peptide-MHC features and do not expect actual se-
quence homology with any existing known epitopes.
A key aspect of our epitope selection process is the
prioritization of overlapping CD4+, CD8+, and B cell epi-
topes. As the role of T cell epitope vaccines in SARS-
CoV-2 continues to be investigated in model systems,
we furthermore cross-referenced human and murine T
cell epitopes to allow for murine vaccine studies using
human-relevant peptides in H2b and H2d haplotypes.
We hypothesize that inclusion of CD8+ epitopes may
allow for clearance of SARS-CoV-2 from infected cells,
and the inclusion of CD4+ epitopes may allow for
greater activation of both cytotoxic and humoral anti-
viral responses. Overlapping CD4+ and CD8+ epitopes
allowed for selection of peptide candidates covering a
large proportion of the population. We next attempted
to identify candidates with overlapping CD4+/CD8+ epi-
topes with B cell epitopes. However, these candidate op-
tions were limited due to the paucity of predicted B cell
candidates. Therefore, a more effective strategy would be
to include overlapping CD4+/CD8+ optimized peptides
together with separate B cell optimized peptides. We ex-
pect this to provide the most robust and broad antiviral
adaptive immune coverage by activating CD4+ T cells,
CD8+ T cells, and B cells.
To this end, we predicted and tested the immunogen-
icity of peptides optimized for both overlapping CD4+/
CD8+ T cell epitopes as well as peptides optimized for B
cell epitopes. We observed statistically significant T cell
activation measured by IFN-y release in response to
seven of our 10 predicted T cell stimulatory epitopes
when administered with poly(I:C) adjuvant as compared
to vaccination with poly(I:C) alone. None of our six pre-
dicted B cell epitopes generated significant T cell activa-
tion, indicating that our method for predicting T cell
immunogenicity is appropriately specific. A 70% success
rate for prediction of T cell epitopes that would activate
T cells to generate significantly enhanced IFN-y release
demonstrates that our computational prediction of pep-
tide vaccines was successful from a T cell standpoint.
Further studies to assess (1) the CD4+ versus CD8+ re-
sponses against each peptide, (2) immunogenicity of in-
dividual epitopes within each peptide, and (3) the
protective capacities of these epitopes are required to
validate their therapeutic potential.
Contrasting these T cell findings, we did not observe
increased antibody response against any of our predicted
B cell epitopes in peptide-vaccinated mice compared to
those vaccinated with adjuvant alone. We also did not
observe any significant antibody response against S pro-
tein above negative control in vaccinated mice. This in-
dicates that while our strategy was successful in
predicting immunogenic T cell epitopes, our predicted B
cell epitopes did not provide robust B cell activation by
day 21. Options to further investigate these results in-
clude titrating dosage of the administered B cell peptides
to evaluate whether concentrations used were sufficient
to generate robust antibody responses, or further refine-
ment of our criteria for B cell epitope prediction in order
to predict epitopes more likely to generate an antibody
response. Whether T cell responses in absence of anti-
body responses are sufficient for antiviral protection
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remains unclear and can be addressed in future viral
challenge studies.
In addition to epitope selection, optimal adjuvant
choice for a SARS-CoV-2 vaccine is currently unclear.
Prior evidence from SARS-CoV-1 suggested a Th2 dom-
inant response to be associated with worse outcomes
[13]—thus, adjuvant selection may also play an import-
ant role in SARS-CoV-2 in skewing the helper arm to-
ward a Th1 phenotype. Patients with severe COVID-19
demonstrate elevated levels of CCR6+ Th17 cells [188].
Additionally, many COVID-19 patients with acute re-
spiratory distress syndrome (ARDS) demonstrated cyto-
kine storm manifested by elevation of a variety of
cytokines, of which several are involved in Th17 re-
sponses [189]. In MERS patients, increased IL-17 to type
I IFN is associated with worse outcome [190].
Altogether, the Th17 response may contribute to in-
creased risk of severe pulmonary injury and worse out-
comes in COVID-19 patients [191]. As the Th1 and
Th17 cellular response pathways are closely linked, co-
therapies that inhibit Th17 activation (e.g., secukinumab,
tocilizumab) have been proposed for use in COVID-19;
however, the efficacy of these therapies remains to be
seen. The role of other helper subsets (Th9, Th18) re-
mains even more poorly understood. Relevant for the
vaccine studies presented here, poly(I:C) appears to pri-
marily activate Th1 cells, skewing the immune response
toward a phenotype that may be most beneficial [192].
Further studies would be needed to assess which sub-
types of T cells were activated by our vaccine
formulations.
One limitation of our study is that, while we use epi-
tope mapping data with direct biological evidence for B
cell epitopes in SARS-CoV-2, the T cell epitopes we re-
port were all derived from computational prediction. In
an effort to partially overcome this weakness, we applied
binding affinity and immunogenicity prediction filters
grounded in validated IEDB binding and tetramer stud-
ies. Other filtering criteria for T cell epitopes have been
evaluated, including allergenicity, antigenicity, stability,
and inflammatory/cytotoxic response [193–195]; it re-
mains to be seen if these or other filtering criteria im-
prove T cell epitope selection in SARS-CoV-2.
Reassuringly, our selection of T cell-directed vaccine
peptides demonstrates significant overlap with the recur-
rent epitopes identified in eight different studies examin-
ing T cell responses in COVID-19 patients (Fig. 7). Le
Bert et al. looked for T cell epitopes within the nucleo-
capsid (N), nsp7 and nsp13 proteins in PBMCs of recov-
ered COVID-19 patients using an IFN-γ ELISpot assay
[196]. They identified two recurrent epitope regions
(N101-120, N321-340) which overlap with multiple
27mer vaccine peptides in this paper (Fig. 6B, peptides
4–8). Shomuradova et al. also identified COVID-19
patient T cell epitopes, but using A*02:01 tetramers
loaded with 13 distinct peptides from the surface
glycoprotein (S) [71]. Two of these 13 peptides showed
recurrent reactivity across 14 A*02:01-positive patients
(S269-277 and S1000-1008). Both of these epitopes are
also included in multiple 27mer vaccine peptides (Fig. 6B,
peptides 11 and 15). Across all eight studies considered,
the most recurrently identified epitopes fall within two
regions, both in the nucleocapsid protein (N) around po-
sitions N100 and N300 (Fig. 7B), overlapping with mul-
tiple vaccine peptides selected by our algorithm. It is
worth noting that our heuristic for selecting abundant
proteins (only considering epitopes and vaccine peptides
from the M, N, and S proteins) was moderately success-
ful in that 15/20 recurrent epitope regions occurred in
these proteins. While we missed recurrent epitope re-
gions in ORF3a, nsp3, nsp12, and nsp13, filtering our
predictions to the most abundant proteins allowed us to
avoid many false positive predictions from ORF1ab and
perform much better in predicting true T cell epitopes.
It is worth noting that the dataset of biologically mea-
sured T cell responses to SARS-CoV-2 infection which
we curated to evaluate our vaccine peptide selection
overlaps significantly with another study by Quadeer
et al. [197]. The biggest difference between their ap-
proach and ours is that we do not require HLA restric-
tion of identified epitope regions and can thus use a
larger number of epitopes from assays such as unbiased
ELISPOT screening. Since our evaluation seeks primarily
to ascertain whether our vaccine peptides are highly
enriched for immunogenic epitopes, we are less stringent
in knowing exactly which epitopes are present and to
which HLA alleles they bind.
A different potential limitation of this study is the in-
sensitivity of our experiments to the total potential space
of SARS-CoV-2 antibody epitopes. Our B cell epitope
analyses start with only 58 identified linear antibody epi-
topes on the surface glycoprotein of SARS-CoV-2, while
it is likely that many other epitopes are possible. Second,
these linear epitope mappings do not allow for identifi-
cation of antibodies which bind tertiary/quaternary pro-
tein structures. Lastly, identification of epitopes via array
studies depended on differences in antibody binding to
potential linear epitopes between uninfected and in-
fected persons. There may be some cross-reactivity be-
tween antibodies generated against other coronaviruses
and SARS-CoV-2, which if present might show reactivity
in our screening assay. If true, our strategy would not
identify these epitopes as specific for SARS-CoV-2. Simi-
larly, we excluded viral regions with significant poly-
morphism across the viral population. We instead
focused on conserved regions of SARS-CoV-2 to identify
epitopes that would be most broadly targetable in the
human population. For these reasons, we do not present
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our antibody data as describing the complete set of
SARS-CoV-2 epitopes.
Conclusions
Our study sought to design a peptide vaccine for SARS-
CoV-2 targeting immune responses from B cells, CD4+
T cells, and CD8+ T cells. This kind of vaccine may be a
useful addition to the evolving landscape of SARS-CoV-
2 vaccines since its rapid manufacturing and precise de-
sign may help fill gaps in immunity that arise due to
antigenic drift of new viral variants. However, we
emphasize that epitope selection is only one aspect of
the problem, and a key question is whether a peptide
vaccine can be sufficiently immunogenic. Adjuvant se-
lection, conjugation to carriers such as KLH [43] or
rTTHC [198], and prime/boost approaches using or-
thogonal platforms are all potential avenues to explore.
Thus far, we have demonstrated the immunogenic cap-
acity of our T cell epitope selection process coupled with
linear peptide vaccination using poly(I:C) as an adjuvant.
It is possible that the selected B cell epitopes in this
work may still be useful for eliciting neutralizing re-
sponses when encoded using a more conformationally
stable immunogen. We anticipate that the sets of vaccine
peptides reported here may be valuable in the preclinical
development of these approaches.
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